Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia
NCT ID: NCT05911438
Last Updated: 2023-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
419 participants
INTERVENTIONAL
2023-07-31
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA)
NCT01012063
An Intravenous Iron Based Protocol for Preoperative Anaemia in Hip and Knee Surgery - An Observational Study
NCT02385383
Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA）
NCT07127042
Effect of Postoperative Ferric Carboxymaltose
NCT03561480
Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty
NCT03561506
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a pilot trial and a formal trial. The pilot trial plans to enroll 20 subjects, with 10 subjects randomly assigned to the experimental group and 10 subjects to the control group. After the successful completion of the pilot trial, its safety and effectiveness, as determined by the investigators, hematologists, orthopedic surgeons, and statisticians, and the formal trial will be initiated. The relevant information and results will also be submitted to the ethics review committee. The formal trial plans to enroll 399 eligible subjects, with a random allocation ratio of 2:1 to the experimental group or the control group.
To ensure the safety of the subjects, the last subject in the pilot trial will be followed up for 21 days after surgery. The safety and effectiveness of the pilot trial results will be discussed by the investigators, hematologists, orthopedic surgeons, and statisticians before initiating the formal trial. The timing of medication, sample size, and visit points in the formal trial may be adjusted appropriately based on the results of the pilot trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)
Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
Basic Treatment
Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
Control group
Basic Treatment
Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ferric Derisomaltose Injection (Monoferric) and Human Erythropoietin Injection (EPIAO)
Ferric Derisomaltose Injection (Monoferric): 1000 mg, intravenous infusion 6±2 days before surgery; Human Erythropoietin Injection (EPIAO): 36000 IU, subcutaneous injection 6±2 days before surgery and 3±1 days after surgery.
Basic Treatment
Daily energy intake of 20-30 kcal/kg, with fat accounting for 20-30% of total energy; Iron: ≥15 mg/d, protein intake of 1.2-1.5 g/kg/d; Simultaneously enhance functional exercises.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who meet the diagnostic criteria for osteoarthritis according to the American College of Rheumatology (ACR) and are undergoing primary total knee arthroplasty due to end-stage osteoarthritis. Flexion deformity \<30°, varus deformity \<30°, valgus deformity \<20°.
* Baseline hemoglobin level: 100g/L \< Hb \< 130g/L.
* No deep venous thrombosis observed on preoperative bilateral lower limb venous color Doppler ultrasound.
* The subject understands and voluntarily signs the written informed consent form (ICF) and is capable of complying with the scheduled visits and related procedures as outlined in the protocol.
Exclusion Criteria
* Mean corpuscular volume (MCV) \> 100 fL.
* Numeric Rating Scale (NRS) score ≥ 3.
* Presence of iron overload (serum ferritin \> 800 ng/ml) or iron utilization disorders (such as hemochromatosis and iron deposition disorders).
* Blood disorders other than iron-deficiency anemia.
* Blood transfusion within the past 30 days.
* Use of iron preparations or HuEPO for the treatment of anemia within the past 30 days.
* History of deep vein thrombosis or pulmonary embolism.
* Patients with hypophosphatemia due to various causes.
* BMI \< 18.5 kg/m2 or body weight \< 50 kg.
* History of recent myocardial infarction, angina pectoris, cerebral infarction, or epileptic seizures within the past 6 months.
* Use of medications affecting coagulation and antiplatelet function within the past week.
* Moderate liver impairment: Decompensated liver cirrhosis or hepatitis, ALT, AST \> 3 times the upper limit of normal (ULN).
* Moderate renal impairment: Serum creatinine (Cr) \> 150 µmol/L.
* HIV or syphilis patients.
* Pregnant or lactating women.
* Participants who have previously participated in other clinical trials, provided the previous investigational drug exposure did not exceed 5 half-lives.
* Acute infection, rheumatoid arthritis, or significant joint inflammation.
* Patients deemed unsuitable to participate in this clinical trial by the investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fuxing Pei
Director of Department of Orthopaedic Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HX-TKA-IV-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.